PCVX logo

Vaxcyte Inc. (PCVX)

$59.40

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PCVX

Market cap

$9.40B

EPS

-8.07

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

1.310861

Price on PCVX

Previous close

$61.61

Today's open

$61.36

Day's range

$59.07 - $62.59

52 week range

$42.40 - $90.75

Profile about PCVX

CEO

Grant E. Pickering

Employees

507

Headquarters

San Carlos, CA

Exchange

Nasdaq Global Select

Shares outstanding

158299981

Issue type

Common Stock

PCVX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on PCVX

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 Across All Ages Studied VAX-31 Adult Indication: Company Expects to Report Results from OPUS-2 and OPUS-3 Phase 3 Trials in First Half of 2027, Supporting Planned Biologics License Application Submission in First Half of 2028 VAX-31 Infant Indication: Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of Phase 2 Dose-Finding Study Expected Either Sequentially or Together by End of First Half of 2027 Phase 1 Study of VAX-A1, the Company's Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus, Advancing to Stage 2 in Adults Pro Forma Cash, Cash Equivalents and Investments of Approximately $3.4 Billion as of September 30, 2026, Including Approximately $1.1 Billion in Net Proceeds from October 2026 Equity and Convertible Senior Notes Offerings SAN CARLOS, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

The mean of analysts' price targets for Vaxcyte (PCVX) points to an 87.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

news source

Zacks Investment Research • Oct 30, 2026

news preview

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

news source

Zacks Investment Research • Oct 14, 2026

news preview

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The shares of common stock, pre-funded warrants and notes to be sold in the offerings are being offered by Vaxcyte. Vaxcyte has granted the underwriters of the common stock and pre-funded warrant offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price per share, and has granted the underwriters of the note offering a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes at the public offering price, solely to cover over-allotments, in each case less underwriting discounts and commissions.

news source

GlobeNewsWire • Oct 7, 2026

news preview

Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027

Vaxcyte remains a 'Strong Buy' after robust phase 3 OPUS-1 results for VAX-31, demonstrating non-inferiority to Prevnar 20 and Capvaxive in adults. The company offers significant upside with multiple 2027 catalysts: OPUS-2 and OPUS-3 phase 3 data for VAX-31 in adults in the 1st half of 2027 and phase 2 infant data. VAX-31 targets broader pneumococcal strain coverage versus current vaccines, addressing emerging serotypes and aiming for 95% adult IPD coverage.

news source

Seeking Alpha • Oct 6, 2026

news preview

Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers

Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.

news source

Investors Business Daily • Oct 6, 2026

news preview

Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial

Vaxcyte said on Monday its experimental ​pneumococcal vaccine generated immune responses comparable to rival vaccines ‌in a late-stage study, sending its shares up 57% in morning trading.

news source

Reuters • Oct 5, 2026

news preview

Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study

Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from Pfizer and Merck.

news source

Investors Business Daily • Oct 5, 2026

news preview

Vaxcyte shares surge on late-stage vaccine trial success

Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-stage study. The results strengthened expectations that VAX-31 could compete with Pfizer's Prevnar 20 and Merck's Capvaxive in the adult pneumococcal vaccine market, which Jefferies estimates could reach $3 billion to $6 billion or more.

news source

Proactive Investors • Oct 5, 2026

news preview

Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial

Vaxcyte NASDAQ: PCVX said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults.

news source

MarketBeat • Oct 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Vaxcyte Inc.

Open an M1 investment account to buy and sell Vaxcyte Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PCVX on M1